560 results on '"Prica, Anca"'
Search Results
102. SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
103. A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)
104. RBC-Enhance: A Randomized Pilot Feasibility Trial of Red Cell Transfusion Thresholds in Myelodysplastic Syndromes
105. Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis.
106. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains.
107. Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis
108. Syngeneic transplants for multiple myeloma – a single center experience and review of the literature
109. Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy
110. Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma
111. Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma
112. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment – validation of official dosing guidelines
113. An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826.
114. IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia
115. INCREASED RISK OF ADVERSE CARDIOVASCULAR EVENTS ASSOCIATED WITH IBRUTINIB USE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A PROPENSITY-MATCHED POPULATION-BASED COHORT STUDY
116. Light Chain Crystal Podocytopathy in a Patient With Systemic Indolent B-Cell Lymphoma
117. Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma‐type post‐transplant lymphoproliferative disorder
118. Evaluation of Lymphadenopathy and Suspected Lymphoma in a Lymphoma Rapid Diagnosis Clinic
119. Abstract A072: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma
120. Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study
121. The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of Overall Survival
122. Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma
123. Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation
124. Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?
125. Positron-emission tomography-based staging is cost-effective in early-stage follicular lymphoma.
126. Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience.
127. Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras
128. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
129. Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer—the 5C study: a study protocol for a randomised controlled phase III trial
130. Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients
131. Effect of PET/CT on the Management and Outcomes of Participants with Hodgkin and Aggressive Non-Hodgkin Lymphoma: A Multicenter Registry
132. Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders
133. Evaluation of Unexplained Lymphadenopathy and Suspected Lymphoma in a Lymphoma Rapid Diagnostic Clinic
134. Functional Predictors of Chemotherapy Toxicity in Elderly Lymphoma Patients: A Prospective Pilot Study
135. Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma
136. Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience
137. Cost-Effectiveness and Cost-Utility Analysis of ABVD Versus Beacopp in the Treatment of Advanced-Stage Hodgkin Lymphoma
138. 47 - Tandem Transplantation in Myeloma Patients with High Risk Cytogenetics: A 10 Year Single-Centre Experience
139. Impact of 18F-fluorodeoxyglucose PET/CT in the management of patients with plasma cell disorders.
140. Significance of treatment response when managing patients with primary central nervous system lymphoma
141. Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation
142. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial
143. Fertility preservation in post-pubescent female cancer patients: A practical guideline for clinicians
144. A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score
145. Financial Impact of Cancer Drug Wastage and Potential Cost Savings From Mitigation Strategies
146. Recurrent Body Rash Warranted Second Desensitization With Acyclovir in a Myeloma Patient: A Case Report
147. Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant
148. Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting
149. A Single-Center Retrospective Study of 140 Patients with Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplantation
150. Results of Salvage Autologous Stem Cell Transplantation (ASCT) for Relapsed Multiple Myeloma (MM) in the Era of Novel Agents: Outcome of Patients (Pts) Receiving Prior Bortezomib (BTZ)-Based Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.